For retatrutide, there is no FDA label yet, but the Phase 3 trial protocols follow similar missed-dose logic
It skips the fermentation phase of the lower digestive tract, so there is no need to worry about it causing small intestinal bacterial overgrowth (SIBO) or Candida infections
Most peptides are broken down in the digestive system before they enter the bloodstream, which makes them ineffective when taken orally
Rapid dose escalation While not definitively established as an independent risk factor, the cases documented in clinical literature all involved standard dose escalation protocols
Zhou B, Li H, Liu J, Xu L, Guo Q, Zang W, et al